Global Diuretic Drugs Market, By Drug Class (Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics, Osmotic Diuretics, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Diuretic Drugs Market Analysis and Size
The global diuretic drugs market is expected to witness significant growth during the forecast period. The increase in renal and kidney disorder cases drives the diuretics drug market. Several new technologies have been developed to help improve the patient's conditions. It is assumed that market for diuretic drugs is majorly hindered by specific adverse effects combined with product discontinuation. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global diuretic drugs market in the forecast period 2022-2029. The expected CAGR of global diuretic drugs market is tend to be around 3.50% in the mentioned forecast period. The market was valued at USD 0.91 billion in 2021, and it would grow upto USD 1.20 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Diuretic, also known as water or fluid pills, are the type of therapeutics that promote urine. Diuretics therapies are used to treat cardiovascular disease and water retention problems by decreasing the amount of salt in the body. It is also given in the treatment of kidney failure and cirrhosis of the liver. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Diuretic Drugs Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Drug Class (Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics, Osmotic Diuretics, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Aurobindo Pharma (India)
Global Diuretic Drugs Market Dynamics
- Rising Incidence of Kidney Diseases
The increase in kidney disorders can be attributed to lifestyle changes such as consumption of unhealthy food high in calcium and other minerals. For instance, per the records of the GBD (Global Burden Disease) 2015 study, about 1.2 million people in the world died because of kidney failure in 2015, a 32% rise since 2005. Thus, this boosts the market growth.
- Growing Mergers and Acquisitions
There were growing mergers and acquisitions for diuretic drugs that are boosting the growth of the market. For instance, GlaxoSmithKline merged with Pfizer in the year 2018 for $12.7 Billion. The merger helped both the companies to deliver cash flows, stronger sales and earnings growth. With the help of this merger, the flagship Diuretic drugs like Biduret and Biduret-L of GSK will take higher advantage of enhanced supply chain network of Pfizer, thus bringing in more sales of drugs. Thus, all this boost the growth of the market.
- Increasing Demand for Retail Pharmacies
The rise in the number of open angle glaucoma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Technological Advancements
Several technological advancements are developed for the improvement of the patients. For instance, a new drug delivery technology known as the oral nanoparticle delivery technology is manufactured to improve the pH and intestinal permeability of the diuretic drugs. Several drugs such as amlodipine and isradipine having low bioavailability and high light sensitivity were delivered using Nano emulsion as a drug delivery system. Thus, it creates opportunity for the market growth.
- Patent Expiration Encourages New Launches
The patent expiration of old companies can create better opportunities for the new market players. Adopting combination therapies is a significant factor contributing to the growth of the diuretic drugs market. Further, R&D fundings are an add-on to the market
- Strict Regulations
Numerous requirements are laid down by the regulatory bodies to manufacture, process and pack the drugs and the companies should obey many compliances such as FDA's CGMP regulations, compliance with European Medicines Agency Regulations, WHO Guidelines. For instance, the Current Good Manufacturing Practice (CGMP) regulations of FDA in the USA enforces numerous regulations under 21 CFR parts 314, 210 and 211, concerning application and licensing of new and generic drugs, regulations for manufacturing, processing, packaging or holding of drugs, and urgent requirements for finished pharmaceuticals respectively.
This global diuretic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global diuretic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Diuretic Drugs Market
During the pandemic, the decline is mainly because of the disruption caused by the lockdown measure across numerous countries to contain COVID-19 spread. There was less demand for genito-urinary drugs mainly as people were staying at home and are less likely to get exposed to factors that might cause genito-urinary infections, or other hormonal diseases caused by lifestyle changes or eating habits. However, the market is expected to rise in the post pandemic era.
Global Diuretic Drugs Market Scope
The global diuretic drugs market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Loop Diuretics
- Ethacrynic acid
- Thiazide Diuretics
- Potassium-Sparing Diuretics
- Osmotic Diuretics
Route of Administration
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Diuretic Drugs Market Regional Analysis/Insights
The global diuretic drugs market is analyzed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global diuretic drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the increase prevalence of cardiovascular complications and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the market's current and future trends. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Diuretic Drugs Market Share Analysis
The global diuretic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global diuretic drugs market.
Key players operating in the global diuretic drugs market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Aurobindo Pharma (India)
- Torrent Pharmaceuticals Ltd (India)